Erick Lucera - 31 Mar 2025 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Financial Officer
Signature
/s/ Ron Caponigro, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
31 Mar 2025
Transactions value $
$0
Form type
4
Filing time
01 Apr 2025, 16:33:30 UTC
Previous filing
28 Mar 2025
Next filing
06 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Award $0 +66.1K $0.00 66.1K 31 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (Right to Buy) Award $0 +215K $0.00 215K 31 Mar 2025 Common Stock 215K $10.46 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 66,100 restricted stock units ("RSU"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest as to 25% of the shares in equal annual installments over four years with the first installment vesting on March 31, 2026, subject to continuous service.
F2 The option was granted on March 31, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 31, 2026, and the remainder vesting in 12 equal quarterly installments thereafter, subject to continuous service.